Spanish biotech SpliceBio has raised $135 million in financing that will help it move a gene-editing therapy for an inherited retinal disease (IRD) through clinical testing. SpliceBio's lead in-house ...
You’ve seen the headlines. Now let’s break them open. Sasha-Ann Simons connects you with the people behind the stories: experts, neighbors and newsmakers who shape the city we share. It’s news, ...
Although studies suggest that perturbing mitotic progression leads to DNA damage and p53 activation, which in turn lead to either cell apoptosis or senescence, it remains unclear how mitotic defects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results